Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatment-naïve Patients: a Systematic Review and Network Meta-Analysis

BACKGROUND: Cabozantinib has recently been evaluated as a first-line treatment in advanced renal cell carcinoma (aRCC). OBJECTIVE: To indirectly assess efficacy of cabozantinib versus standard-of-care (SoC) comparators in the first-line treatment of aRCC. METHODS: We conducted a systematic literatur...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Target Oncol
Prif Awduron: Schmidt, Elvira, Lister, Johanna, Neumann, Monika, Wiecek, Witold, Fu, Shuai, Vataire, Anne-Lise, Sostar, Jelena, Huang, Shengnan, Marteau, Florence
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Springer International Publishing 2018
Pynciau:
Original Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5887000/
https://ncbi.nlm.nih.gov/pubmed/29492762
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-018-0559-0
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg